News | January 30, 2015

Agreement demonstrates commitment to secure continuous supply of Xenon 133 to U.S. medical market through 2016 and beyond

Contrast media, Nuclear imaging, Radiopharmaceuticals and tracers
Image courtesy of Lantheus

January 30, 2015 — Lantheus Medical Imaging Inc. announced an agreement with the Institute for Radioelements (IRE) for the future supply of Xenon Xe 133 Gas (Xenon 133). Currently, Lantheus is the only U.S. manufacturer of Xenon 133, which is an inhaled radiopharmaceutical imaging agent used for the evaluation of pulmonary function and for imaging the lungs, as well as the assessment of cerebral blood flow.  

Under the terms of the agreement, IRE will provide bulk Xenon 133 to Lantheus for processing and finishing, once development work has been completed and all necessary regulatory approvals have been obtained. Lantheus estimates commercial production will occur in 2016.

For more information: www.lantheus.com, www.ire.eu

 

 

 

 

 

 

Related Content

News | Radiation Therapy

October 7, 2021 — NANOBIOTIX, a late-stage clinical biotechnology company pioneering physics-based approaches to expand ...

Time October 07, 2021
arrow
Feature | Cardiac Imaging

October 6, 2021 – A new study published in Radiology: Cardiothoracic Imaging on cardiac imaging trends over a decade ...

Time October 06, 2021
arrow
News | Ultrasound Imaging

October 5, 2021 — Ultrasound experts urged the health care community to work to expand utilization of ultrasound ...

Time October 05, 2021
arrow
News | Magnetic Resonance Imaging (MRI)

September 20, 2021 — Gadolinium-based contrast agents, the gold standard in magnetic resonance imaging (MRI) to ...

Time September 20, 2021
arrow
News | Radiation Oncology

September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and ...

Time September 17, 2021
arrow
News | Radiopharmaceuticals and Tracers

September 17, 2021 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time September 17, 2021
arrow
News | Contrast Media Injectors

September 16, 2021 — FDB (First Databank), a leading provider of drug and medical device knowledge that helps healthcare ...

Time September 16, 2021
arrow
Feature | Nuclear Imaging | By Staff of the American Society of Nuclear Cardiology (ASNC)

A year after COVID-19 turned the world upside down, the American Society of Nuclear Cardiology (ASNC) asked members how ...

Time September 16, 2021
arrow
News | Radiopharmaceuticals and Tracers

September 10, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time September 10, 2021
arrow
News | PET Imaging

September 3, 2021 — Eckert & Ziegler Radiopharma GmbH has successfully submitted an amendment to their Drug Master File ...

Time September 03, 2021
arrow
Subscribe Now